Hims & Hers Health, Inc.
Long
Aktualisiert

HIMS - June 24 Qullamaggie Breakout and Episodic Pivot

345
I believe the inclusion of the compounded GLP-1 drug as part of their product offerings will driving strong sales and membership numbers in the next few months.

1) Their compounded GLP-1 is significantly cheaper
2) Their platform makes it easier and more accessible to purchase
3) It is lifestyle related so monthly recurring purchases is encouraged
4) HIMS is essentially a DTC business where capturing market share is crucial at this stage. In 2021 it was reported that they spend 48% of their revenue on marketing.

As long as they can secure recurring purchases with a solid Average Order Value (AOV), they can gradually reduce and optimise expenses for new acquisitions once they have captured a significant market share. Not to mention the cross sell potential and the lower advertising costs for existing customers

This is part of a Qullamaggie Breakout and Episodic Pivot study I am currently conducting

Source
Anmerkung
Initially, I focused on the tightening candles. However, the price momentum, reflected in the gap up, combined with my conviction based on the fundamental reasons for the stock's rise. Consequently, I entered the trade with confidence. If the price pulls back due to broad market movements, I'll be ready to re-enter another probe bet once momentum returns.
Trade wurde manuell geschlossen
I closed this trade at breakeven because the price didn't follow the expected trend and started to consolidate. I will re-enter when the momentum aligns with my hypothesis and conviction.

Haftungsausschluss

Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.